Notable Launches Therapeutic Pipeline by Acquiring Worldwide Development and Commercialization Rights to Volasertib
Summary
Volasertib is a Polo-like kinase 1 (PLK-1) inhibitor with demonstrated activity in acute myeloid leukemia (AML) and other tumor types with significant unmet medical need. Notable’s proprietary platform was built upon deep expertise across therapeutics, diagnostics, software, engineering, machine learning and automation. “We targeted and licensed volasertib because of its compelling performance on our Predictive Precision Medicine Platform and as an important addition to our growing clinical pipeline. We plan to fast-track volasertib’s development with phase 2/3 clinical trials in AML and other cancers, selectively enrolling patients who are predicted to respond.” Dr. Bock added, “With the power of our high-fidelity prediction platform, volasertib represents just one of many compelling opportunities to match highly promising clinical candidates with the optimal patient population. We are thrilled to be at the forefront in the field of predictive precision medicines and advance with the sense of urgency that patients with life-threatening conditions deserve.” Under terms of the agreement, Notable will have exclusive rights to develop and commercialize volasertib in leukemias, lymphomas and other adult cancer indications.